Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PT Indofarma Tbk's Enterprise Value is Rp1,118,378 Mil.
PT Indofarma Tbk's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was Rp-41,017 Mil. Therefore, PT Indofarma Tbk's EV-to-EBIT ratio for today is -27.27.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, PT Indofarma Tbk's Enterprise Value is Rp1,118,378 Mil.
PT Indofarma Tbk's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was Rp-39,897 Mil. Therefore, PT Indofarma Tbk's EV-to-EBITDA ratio for today is -28.03.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, PT Indofarma Tbk's Enterprise Value is Rp1,118,378 Mil.
PT Indofarma Tbk's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was Rp151,551 Mil. Therefore, PT Indofarma Tbk's EV-to-Revenue ratio for today is 7.38.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, PT Indofarma Tbk's Enterprise Value is Rp1,118,378 Mil.
PT Indofarma Tbk's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was Rp-209,982 Mil. Therefore, PT Indofarma Tbk's EV-to-FCF ratio for today is -5.33.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
PT Indofarma Tbk (ISX:INAF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
PT Indofarma Tbk's current Enterprise Value is Rp1,118,378 Mil.
PT Indofarma Tbk's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-41,017 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
PT Indofarma Tbk's current Enterprise Value is Rp1,118,378 Mil.
PT Indofarma Tbk's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-39,897 Mil.
PT Indofarma Tbk's current Enterprise Value is Rp1,118,378 Mil.
PT Indofarma Tbk's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp151,551 Mil.
PT Indofarma Tbk's current Enterprise Value is Rp1,118,378 Mil.
PT Indofarma Tbk's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-209,982 Mil.
PT Indofarma Tbk's current Enterprise Value is Rp1,118,378 Mil.
PT Indofarma Tbk's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-209,982 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Indofarma Tbk Enterprise Value Related Terms
PT Indofarma Tbk Enterprise Value Historical Data
* Premium members only.
The historical data trend for PT Indofarma Tbk's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:INAF vs ZTS, VTRS, NBIX: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Indofarma Tbk's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Indofarma Tbk Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Indofarma Tbk's Enterprise Value distribution charts can be found below:
* The bar in red indicates where PT Indofarma Tbk's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
PT Indofarma Tbk's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of Rp1,118,378 Mil mean?
PT Indofarma Tbk (ISX:INAF) has a Enterprise Value of Rp1,118,378 Mil as of Jun. 30, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on PT Indofarma Tbk and its competitors.
Is PT Indofarma Tbk's Enterprise Value too high?
PT Indofarma Tbk's current Enterprise Value is Rp1,118,378 Mil. Overall, PT Indofarma Tbk has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does PT Indofarma Tbk's Enterprise Value compare to ZTS and VTRS?
PT Indofarma Tbk's Enterprise Value of Rp1,118,378 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on PT Indofarma Tbk and its competitors. PT Indofarma Tbk's current Enterprise Value is Rp1,118,378 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Indofarma Tbk stock overvalued right now?
PT Indofarma Tbk (ISX:INAF) has a current Enterprise Value of Rp1,118,378 Mil. The stock's GF Value™ is Rp176.99, compared to a current price of Rp126.00 — trading 28.8% below its estimated fair value. The current Enterprise Value is Rp1,118,378 Mil. PT Indofarma Tbk's overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For PT Indofarma Tbk (ISX:INAF), the current Enterprise Value is Rp1,118,378 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued.
The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.
Key valuation signals for ISX:INAF:
Enterprise Value: Rp1,118,378 Mil
GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.
8GF Score
Get the complete analysis for ISX:INAF
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:INAF has been successfully added to your 
